Popular obesity stocks fell on Tuesday after pharma giant Eli Lilly LLY lowered its sales guidance for full-year 2024 and announced disappointing preliminary fourth-quarter sales numbers. LLY’s ...

The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, ...

Eli Lilly is just weeks ... the drug in the multi-shot pen injector format. Like the earlier single-dose version, which was approved by the MHRA last year, the Mounjaro KwikPen can be used to ...

The Food and Drug Administration (FDA) has reaffirmed that Mounjaro ... tirzepatide injection product shortage is resolved,” the agency said in a letter to Patty Donnelly, Eli Lilly senior ...

Shares of Eli Lilly were taking a 6.9% hit toward a two-month low in recent trading, enough to make them the S&P 500's biggest decliner. The problem is that the drug giant provided fourth-quarter ...

The FDA removed Eli Lilly’s LLY tirzepatide injection products from the drug ... a dual GIP and GLP-1 receptor agonist (GIP/GLP-1 RA), as Mounjaro for type II diabetes (T2D) and Zepbound for ...

Eli Lilly shares fell after the drugmaker warned that sales of its hot diabetes and anti-obesity drugs are growing more slowly than expected. Lilly now expects fourth-quarter sales of $3.5 billion for ...

Eli Lilly & Co.’s diabetes and weight-loss drugs Mounjaro and Zepbound are no longer ... “The tirzepatide injection shortage is resolved,” the US Food and Drug Administration said Thursday ...

Chris Schott, an analyst from J.P. Morgan, maintained the Buy rating on Eli Lilly & Co (LLY – Research Report). The associated price target ...

Peptide drugs, such as the metabolic medicines Mounjaro and Zepbound from Eli Lilly, must be administered ... biologic drugs administered by injection. Peptides are chains of amino acids.